Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alyssa Lyon

Sports Medicine Hammond, LA Medical Doctor

NPI 1538350996 CMS profile 1232632

15790 Paul Vega MD Dr, Hammond, LA 70403

Open in the dashboard

General payments

$445

13 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alyssa Lyon of Hammond, LA is reported in the CMS Open Payments database as having received $445 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $144 2
2023 General $145 1
2020 General $128 8
2019 General $27 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alyssa Lyon
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Alyssa Lyon were reported at $144. Among 51 Sports Medicine profiles paid that year, the median was $100 and the middle half received between $29 and $262.

Show as a table
Year Alyssa Lyon Sports Medicine median Middle half National median
2019 $27 $76 $23–$220 $163
2020 $128 $31 $20–$164 $114
2021 $0 $65 $24–$146 $132
2022 $0 $47 $26–$178 $149
2023 $145 $73 $31–$176 $160
2024 $0 $66 $25–$173 $164
2025 $144 $100 $29–$262 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $168 3 payments
  2. Medline Industries, Inc. $145 1 payment
  3. GlaxoSmithKline, LLC. $39 3 payments
  4. Amgen Inc. $36 2 payments
  5. Smith+Nephew, Inc. $17 1 payment
  6. Novo Nordisk Inc $15 1 payment
  7. Teva Pharmaceuticals USA, Inc. $14 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $445 13 payments
Products named General payments · program years 2019–2025
  1. AIRSUPRA $127 1 payment
  2. EVENITY $36 2 payments
  3. Prolia $36 2 payments
  4. TRELEGY ELLIPTA $27 2 payments
  5. LOKELMA $24 1 payment
  6. SPIRIVA RESPIMAT $23 2 payments
  7. REGRANEX $17 1 payment
  8. Santyl $17 1 payment
  9. BREZTRI $17 1 payment
  10. RYBELSUS $15 1 payment
  11. Other $51 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

559

Median for Emergency Medicine: 88

Drug cost

$5,357

Median for Emergency Medicine: $590

Branded share of claims

24.9%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 55 $1,097
Albuterol Sulfate Hfa Albuterol Sulfate Brand 34 $984
Cefdinir Generic 44 $604
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 38 $337
Mupirocin Generic 41 $318
Oseltamivir Phosphate Generic 11 $301
Moxifloxacin Moxifloxacin Hcl Brand 14 $286
Doxycycline Hyclate Generic 52 $247
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 20 $231
Cephalexin Generic 51 $222

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$25,050

Of which drugs: $111

Medicare patients

212

Average age 75

Services billed

501

139 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 49%
Ischemic heart disease 33%
Depression 23%
Osteoporosis 22%
Chronic kidney disease 21%
Diabetes 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record